<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00893711</url>
  </required_header>
  <id_info>
    <org_study_id>FS-2009</org_study_id>
    <nct_id>NCT00893711</nct_id>
  </id_info>
  <brief_title>Lactobacillus Reuteri Versus Placebo in the Treatment and Prevention of Infantile Colic</brief_title>
  <official_title>Lactobacillus Reuteri Versus Placebo in the Treatment and Prevention of Infantile Colic: a Clinical and Microbiological, Double-blind, Prospective, Randomised, Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:

        -  to study the intestinal microflora of colicky infants before and after L. reuteri or
           placebo administration, evaluating the effect of Lactobacillus reuteri on the growth of
           the main intestinal microbiota (coliforms, Clostridium butyricum, Lactobacilli,
           Bifidobacteria) with fluorescent in situ hybridization (FISH) technique or with
           Real-Time PCR Taqman; Further, the global intestinal microflora composition, using
           large-scale DNA sequencing of 16S rRNA genes ( 454-pyrosequencing technique.

        -  to evaluate the improvement of colicky symptoms by the oral administration of
           Lactobacillus reuteri (primary outcome: reduction of the daily average crying time from
           baseline to the end of the treatment period, to less than 3 hours a day, the cut-off
           proposed by Wessel; secondary outcome: number of responders versus non-responders in
           each group at the end of the treatment).

        -  to evaluate fecal calprotectin values at the beginning and at the end of the study.
           BÜHLMANN Quantum Blue® Calprotectin High Range (Schönenbuch, Switzerland). A
           quantitative immunoassay.

        -  to evaluate Th17/Treg balance at time 0 and t 30 ( days) investigating mRNA FOXP3 and
           RORγ in peripheral blood using RT-PCR Real Time Taqman.

        -  Parental satisfaction at the end of the study period ( 30 day ) with a numerc scale from
           1 to 10.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infantile colic is one of the most common problems within the first three months of life. It
      consists of a behavioural syndrome characterised by paroxysmal, excessive and inconsolable
      crying without identifiable cause. Although infantile colic is commonly reported and causes
      appreciable distress for both parents and paediatricians, despite forty years of research,
      its aetiology still remains unclear. Recently the role of intestinal microflora has growing
      importance, and a lower count of intestinal lactobacilli has been observed in colicky infants
      compared to healthy ones. In a recent study we have observed that Lactobacillus reuteri
      improved colicky symptoms in breast-fed infants within one week of treatment compared to
      Simethicone, suggesting that probiotics may play a role in infantile colic (Savino F, Pelle
      E, Palumeri E, Oggero R, Miniero R.Lactobacillus reuteri (American Type Culture Collection
      Strain 55730) versus simethicone in the treatment of infantile colic: a prospective
      randomized study. Pediatrics 2007; 119:e124-30). The mechanism involved in such finding is
      only partially understood and, for this reason, we have planned this new study to evaluate
      not only the clinical improvement but also the microbiological data.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of the daily average crying time from baseline to the end of the treatment period, to less than 3 hours a day, the cut-off proposed by Wessel and number of responders versus non-responders in each group at the end of the treatment</measure>
    <time_frame>time 0 - 7 - 21 - 30 days</time_frame>
    <description>diary crying Barr</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Responders to treatment</measure>
    <time_frame>30 day</time_frame>
    <description>was defined as the number of responders in each group on days 7, 14 , 21 and 30 . Responders (defined in the protocol) were those who experienced a decrease in the daily average crying time of 50% from baseline. Diary Crying Barr.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To analyze intestinal microflora</measure>
    <time_frame>day 0 and day 30</time_frame>
    <description>The intestinal microflora of the infants will be analyzed the effect of the probiotic on selected intestinal microbiota (Escherichia coli, Clostridium butyricum, Lactobacillus, Bifidobacterium), using fluorescent in situ hybridization (FISH) or using with Real-Time PCR Taqman.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assay of Th17/Treg balance</measure>
    <time_frame>time 0- 30 days</time_frame>
    <description>For the analyses of mRNA FOXP3 and RORγ in peripheral blood RT-PCR Real Time Taqman will be used</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Preventive effects of L.reuteri on infantile colic</measure>
    <time_frame>5 months</time_frame>
    <description>action on: use of pain relieving agents, switch to infant formula, number of paediatric consultations for infantile colic</description>
  </other_outcome>
  <other_outcome>
    <measure>Fecal calprotectin values</measure>
    <time_frame>0-30 days</time_frame>
    <description>BÜHLMANN Quantum Blue® Calprotectin High Range (Schönenbuch, Switzerland). It is a quantitative determination of fecal calprotectin through a sandwich immunoassay.</description>
  </other_outcome>
  <other_outcome>
    <measure>Parental satisfacion</measure>
    <time_frame>day 30</time_frame>
    <description>numeric scale from 1to 10</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">155</enrollment>
  <condition>Infantile Colic</condition>
  <arm_group>
    <arm_group_label>Lactobacillus reuteri</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lactobacillus reuteri DSM 17938 is administered at a dose of 1.000.000.000 colony forming units (CFU) in V drops of a commercially available oil suspension, 30 min before feeding, once a day for 30 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is administered in V drops once a day for 30 days. Placebo is inactive, similar to the studied treatment with the same package, taste, characteristics of colour and consistency.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L.reuteri + vit D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>L. reuteri DSM 17938 (10^8 CFU) plus vitamin D3 (400 UI) five drops/day for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vit D Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>vitamin D3 (400 UI) five drops/day for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lactobacillus reuteri DSM 17938</intervention_name>
    <description>Lactobacillus reuteri is administered at a dose of 1.000.000.000 colony forming units (CFU) in V drops/day for 21 days</description>
    <arm_group_label>Lactobacillus reuteri</arm_group_label>
    <other_name>Reuterin, BIOGAIA - Sweden</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is administered in V drops once a day for 21 days. Placebo is inactive, similar to the studied treatment with the same package, taste, characteristics of colour and consistency.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo BIOGAIA Sweden</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L.reuteri + Vit D</intervention_name>
    <arm_group_label>L.reuteri + vit D</arm_group_label>
    <other_name>Reuterin D3 drops, Noos Italy</other_name>
    <other_name>Reuflor D3 drops, Italchimici Italy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vit D placebo</intervention_name>
    <arm_group_label>Vit D Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of infantile colic according to Wessel's criteria

          -  gestational age between 37 and 42 weeks

          -  age between 4 and 16 weeks

          -  birth weight between 2500 and 4000 g

          -  exclusively breastfed

        Exclusion Criteria:

          -  clinical evidence of chronic illness or gastrointestinal disorders

          -  administration of probiotics and antibiotics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Savino, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Infantile Regina Margherita - Dipartimento di Pediatria Generale e Specialistica. S.S. D. Sub Intensiva Allargata della Prima Infanzia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesco Savino, MD, PhD</last_name>
    <phone>00390113135618</phone>
    <email>francesco.savino@unito.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ospedale Infantile Regina Margherita</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Savino, MD PhD</last_name>
      <phone>+39 0113135618</phone>
      <email>francesco.savino@unito.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Savino, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Infantile Regina Margherita</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Savino, MD, PhD</last_name>
      <phone>00390113135224</phone>
      <email>francesco.savino@unito.it</email>
    </contact>
    <investigator>
      <last_name>Valentina Tarasco, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisabetta Palumeri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emanuela Locatelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diego Matteuzzi, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lisa Cordisco, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberto Oggero, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emanuele Castagno, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberto Calabrese, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Roos, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simone Ceratto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angela De Marco, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Garro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvia Nicoli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Massimiliano Bergallo, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paola Montanari, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ilaria Galliano, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Infantile Regina Margherita</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Savino, MD, PhD</last_name>
      <phone>+390113135618</phone>
      <email>francesco.savino@unito.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Savino, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Garrro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Massimiliano Bergallo, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Savino F. Focus on infantile colic. Acta Paediatr. 2007 Sep;96(9):1259-64. Review.</citation>
    <PMID>17718777</PMID>
  </reference>
  <reference>
    <citation>Savino F, Pelle E, Castagno E, Palumeri E, Oggero R. Must infants with colic really be hospitalized? Acta Paediatr. 2007 Jul;96(7):1109; author reply 1110. Epub 2007 May 10.</citation>
    <PMID>17498186</PMID>
  </reference>
  <reference>
    <citation>Savino F, Pelle E, Palumeri E, Oggero R, Miniero R. Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study. Pediatrics. 2007 Jan;119(1):e124-30.</citation>
    <PMID>17200238</PMID>
  </reference>
  <reference>
    <citation>Savino F, Grassino EC, Guidi C, Oggero R, Silvestro L, Miniero R. Ghrelin and motilin concentration in colicky infants. Acta Paediatr. 2006 Jun;95(6):738-41.</citation>
    <PMID>16754557</PMID>
  </reference>
  <reference>
    <citation>Savino F, Palumeri E, Castagno E, Cresi F, Dalmasso P, Cavallo F, Oggero R. Reduction of crying episodes owing to infantile colic: A randomized controlled study on the efficacy of a new infant formula. Eur J Clin Nutr. 2006 Nov;60(11):1304-10. Epub 2006 May 31.</citation>
    <PMID>16736065</PMID>
  </reference>
  <reference>
    <citation>Savino F, Castagno E, Bretto R, Brondello C, Palumeri E, Oggero R. A prospective 10-year study on children who had severe infantile colic. Acta Paediatr Suppl. 2005 Oct;94(449):129-32.</citation>
    <PMID>16214780</PMID>
  </reference>
  <reference>
    <citation>Savino F, Cresi F, Castagno E, Silvestro L, Oggero R. A randomized double-blind placebo-controlled trial of a standardized extract of Matricariae recutita, Foeniculum vulgare and Melissa officinalis (ColiMil) in the treatment of breastfed colicky infants. Phytother Res. 2005 Apr;19(4):335-40.</citation>
    <PMID>16041731</PMID>
  </reference>
  <reference>
    <citation>Savino F, Bailo E, Oggero R, Tullio V, Roana J, Carlone N, Cuffini AM, Silvestro L. Bacterial counts of intestinal Lactobacillus species in infants with colic. Pediatr Allergy Immunol. 2005 Feb;16(1):72-5.</citation>
    <PMID>15693915</PMID>
  </reference>
  <reference>
    <citation>Savino F, Cresi F, Pautasso S, Palumeri E, Tullio V, Roana J, Silvestro L, Oggero R. Intestinal microflora in breastfed colicky and non-colicky infants. Acta Paediatr. 2004 Jun;93(6):825-9.</citation>
    <PMID>15244234</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2009</study_first_submitted>
  <study_first_submitted_qc>May 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2009</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna</investigator_affiliation>
    <investigator_full_name>Dr. SAVINO Francesco</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>infantile colic</keyword>
  <keyword>lactobacillus</keyword>
  <keyword>gut microflora</keyword>
  <keyword>FISH</keyword>
  <keyword>toll like receptor</keyword>
  <keyword>T reg</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>to partecipe to an individual partecipant data meta- analysis.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

